Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Speculative but strong event-driven momentum after FDA agreed on a resubmission path for RP1 plus nivolumab melanoma BLA, with supportive ASCO clinical updates and roughly 132% gain over 20 trading days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Net Cash ⢠Rapid Cash Burn ⢠Ongoing Dilution REPL has strong net cash and liquidity, but rapid cash burn, no revenue, heavy R&D losses, rising leverage, and shareholder dilution create significant funding and execution risk.
Price Behavior
Key Price Behavior Insights: ⢠Lower highs ⢠Support test ⢠Elevated RSI Support Level: $12.87â$12.92 Resistance Level: $13.20â$13.30; $14.45â$14.77 REPL is in a short-term downtrend; defend $12.87â$12.92 and reclaim $13.30 to improve the setup, while a break below support risks further volatility.
Sentiment & News
Key News Insights: ⢠Securities Litigation ⢠FDA Disclosure ⢠Share Decline Replimune faces securities class-action scrutiny over alleged undisclosed FDA concerns surrounding RP1 trial design and efficacy evidence, heightening investor risk after a sharp share-price decline.
AI Summary
REPL's investment case hinges on verifying TujuCare's true FDA/label status and proving early launch adoption fast enough to offset roughly $76M quarterly cash burn and avoid dilutive financing; absent confirmed revenue traction, the stock appears to price in more success than its balance sheet supports.
Description
Replimune Group, Inc. is a biotechnology company developing oncolytic immuno-gene therapies for cancer using its proprietary Immunotherapy platform. Its lead candidate, RP1, is a selectively replicating herpes simplex virus 1 therapy being evaluated in clinical trials for solid tumors and cutaneous squamous cell carcinoma, alongside earlier-stage programs including RP2 and RP3. The company was founded in 2015 and is based in Woburn, Massachusetts.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jun 22 | Jun 29 | REPL | Replimune Group, Inc. | Speculative but strong event-driven momentum after FDA agreed on a resubmission path for RP1 plus nivolumab melanoma BLA, with supportive ASCO clinical updates and roughly 132% gain over 20 trading days. | Closed | +0.2% |
| Jun 10 | Jun 17 | REPL | Replimune Group, Inc. | Speculative biotech momentum candidate: stock rose about 113% over 21 trading days, helped by 2026-05-29 FDA alignment on a path forward for RP1 plus nivolumab BLA resubmission/reconsideration and ASCO clinical updates on 2026-05-30 and 2026-05-31. | Closed | +18.1% |